Deramiocel (Cap-1002) retweeted
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible.
Read the press release: bit.ly/4BMIYM5
#AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
Deramiocel (Cap-1002) retweeted
Today, we make Duchenne seen. 💙
Awareness starts with understanding. Share, learn, and help more people know Duchenne.
Learn more at Cureduchenne.org
#WorldDuchenneAwarenessDay #DuchenneAwareness #CureDuchenne #Duchenne #DuchenneMuscularDystrophy
Deramiocel (Cap-1002) retweeted
Today, we join the global community in recognizing World Duchenne Awareness Day. This year’s theme, “Access Changes Lives,” reminds us that meaningful progress goes beyond just scientific breakthroughs. It means ensuring that individuals living with Duchenne and Becker muscular dystrophy have access to the care, support, and opportunities they need. At Capricor, we remain committed to continuing to push forward with Deramiocel and our mission to help make a difference in the lives of those living with DMD. Together, we can raise awareness, inspire action, and work toward a brighter future for the Duchenne community. 💚
$CAPR #WDAD2026 #DuchenneAwareness #DMD #AccessChangesLives #Deramiocel
Deramiocel (Cap-1002) retweeted
PPMD, in collaboration with #Duchenne advocacy partners Best Day Ever Foundation, @CureDuchenne, @JettFoundation, @KindnessOverMD, @LHF_EndDuchenne, @MDAorg, MDFF, and @TeamJosephInfo, invites you to join a webinar on July 7 at 2 PM ET...
Register now: parentprojectmd.org/events/w…
Deramiocel (Cap-1002) retweeted
Let the phrase “time is muscle” actually mean something and get this approved immediately!
This quoted post is unavailable.
Deramiocel (Cap-1002) retweeted
Happy Mother’s Day 💙
The love, strength, and fierce dedication of Duchenne moms and mom figures is unmatched—and today, we’re celebrating all of you.
Thank you for being the heart of this community and for everything you do, seen and unseen.
#MothersDay #Mom
Deramiocel (Cap-1002) retweeted
At the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Capricor will be presenting Phase 3 HOPE-3 results for Deramiocel in a late-breaking oral presentation later today. The presentation highlights previously reported topline data demonstrating significant functional benefits in patients with Duchenne muscular dystrophy (DMD). For more information, please click bit.ly/4cXjCAt
$CAPR #Deramiocel #DMD #AANAM #Duchenne
Deramiocel (Cap-1002) retweeted
Exosomes deliver key reproductive signals between neurons, revealing new biology. - @uOttawa exosome-rna.com/researchers-…
Deramiocel (Cap-1002) retweeted
Today, we celebrate the incredible siblings in our CureDuchenne community 💙
You are advocates, teammates and best friends. Your role is powerful, and your impact is immeasurable.
We see you and we appreciate you.
#NationalSiblingsDay #DMD #Siblings #DuchenneCommunity
Deramiocel (Cap-1002) retweeted
Arnold Ventures (founded by John Arnold) is laser-focused on FDA accountability. They demand rigorous Phase 3 RCTs, confirmed clinical benefits, and no more surrogate-endpoint shortcuts that fail patients (they’ve repeatedly called out eteplirsen-style approvals in DMD as exactly what’s wrong with the system).
Deramiocel from Capricor checks every single box they want:
1. Not accelerated approval- full BLA seeking traditional approval.
2. Pivotal Phase 3 HOPE-3 trial (randomized, double-blind, placebo-controlled) just hit its primary endpoint.
3. Real, meaningful clinical outcomes:
- 54% reduction in upper-limb function decline
- 91% slowing of cardiac decline
- Cardiac MRI data showing actual reduction in fibrotic segments (late gadolinium enhancement)
This isn’t hype on a biomarker — it’s disease-modifying data on both skeletal muscle AND cardiomyopathy, the #1 cause of death in DMD.
Exactly what Arnold Ventures has been begging the FDA to require: strong, confirmatory evidence BEFORE approval so patients and payers actually get value.
PDUFA date: August 22, 2026 BLA already back under active review after the CRL was lifted this month
If Arnold Ventures had to design the ideal next DMD therapy to restore trust in the approval process… this is it.
$CAPR patients win. Evidence wins. The system wins.
What do you think — will AV publicly praise this one? 👀
#DMD #Deramiocel #CAPR #RareDisease #FDA @DrMakaryFDA
CEO of @Capricor @linda_marban on what clinicians should know about the company's investigational #Duchenne #celltherapy Deramiocel.
#MDAconference (@MDAorg)
Deramiocel (Cap-1002) retweeted
Today we announced that the U.S. FDA has resumed review of our BLA for Deramiocel for the treatment of Duchenne muscular dystrophy and set a PDUFA target action date of August 22, 2026.
Click here to read the announcement: bit.ly/4bz2qk2
#DMD #Deramiocel $CAPR
Deramiocel (Cap-1002) retweeted
Mr. President, I’m calling on you to act on Capricor’s Duchenne therapy and save hearts and lives, including mine!
Let’s unleash American innovation and continue to be the medical leader in the world. Mr. President you can this happen and make history in DMD by ensuring the swift approval of deramiocel!
USA USA USA 🇺🇸🇺🇸🇺🇸
@realDonaldTrump @WhiteHouse @EricTrump @DonaldJTrumpJr @POTUS @JDVance redstate.com/redstate-guest-…
Deramiocel (Cap-1002) retweeted
I just wrote a letter to the FDA urging them to review @Capricor’s deramiocel quickly after positive Phase III data so patients can get access sooner. ONLY if you’re a DMD patient or a parent waiting for this treatment, please sign your name here: submit.jotform.com/253445274…
Let’s HOPE the FDA moves fast!
Deramiocel (Cap-1002) retweeted
Please consider donating to our charity climb and also to support our first ever Duchenne specific workshop in Malaysia! spot.fund/2jzgqd7dc
Deramiocel (Cap-1002) retweeted
Today I saw my doctor, and for the first time in my life, we’ve seen a decline in my heart EF. As my doctor put it: “You have time, but you don’t have forever.” GAME TIME FOR ME.
The timing is perfect for the FDA to approve Deramiocel, which has been shown to stabilize—and even improve—heart function over four years and counting, measured via cardiac MRI. This is an objective measurement. You can’t wish your heart to improve or try harder on the test. It is what it is. That’s why the data is so striking and encouraging.
In my opinion, we are at a crossroads where DMD can soon be a non-fatal disease—and Deramiocel is a giant part of making that happen.
Today, @Capricor —the biotech behind Deramiocel—put out a letter to the DMD community, which you’ll see below.
August 31st — ALL EYES ON THE FDA!
Deramiocel (Cap-1002) retweeted
The interview was in Spanish… I’d recommend the original version, but the facts convey.
@SmidtHeart
#InterviewsCNIC 🎙️ @MarbanLab
🗣️ ‘We have designed a cellular product for #Duchenne muscular dystrophy, called Deramiocel, and we have had positive results in at least two clinical trials’. Dr. Marbán is founding director of @SmidtHeart and his lab intensively studies cardiac progenitor cells, their origins and therapeutic potential. 🫀🔬
Find out more in this #interview for #CNICPulse. Link in comments! 👇
#Science #CardiovascularResearch #CVD
Deramiocel (Cap-1002) retweeted
Capricor is pleased to announce that the U.S. FDA has granted Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening our focus in neuromuscular diseases. Read the full press release: bit.ly/3SV7Uf2
$CAPR #Deramiocel #RareDisease #MuscularDystrophy
Deramiocel (Cap-1002) retweeted
Fresh insights on heart health in #Duchenne!🫀
New research underscores the value of early cardiac treatment in DMD, helping to preserve heart function and delay cardiomyopathy-related complications.
Check out the full article: ow.ly/4GxH50Wa41R
#Deramiocel #Cardiac





















